Concomitant cyclophosphamide and oral immunosuppressants with rituximab for systemic lupus erythematosus SIR, Turner-Stokes et al. [1] recently published their experience using repeat cycles of rituximab in SLE. We welcome this addition to the evidence base for rituximab. We recently published our experience using rituximab in SLE in 41 patients [2]. In general, we agree with the observations of the University College London (UCL) group in terms of response rates and time to relapse. However, there are two important differences in our treatment protocol: (i) we did not routinely use concomitant CYC and (ii) we did not discontinue concomitant oral immunosuppressants if taken at baseline. Comparison of the findings of our studies is therefore of interest.
SIR, Turner-Stokes et al. [1] recently published their experience using repeat cycles of rituximab in SLE. We welcome this addition to the evidence base for rituximab. We recently published our experience using rituximab in SLE in 41 patients [2] . In general, we agree with the observations of the University College London (UCL) group in terms of response rates and time to relapse. However, there are two important differences in our treatment protocol: (i) we did not routinely use concomitant CYC and (ii) we did not discontinue concomitant oral immunosuppressants if taken at baseline. Comparison of the findings of our studies is therefore of interest.
We used the original BILAG and the scoring A = 9, B = 3, C = 1 and the UCL group used British Isles Lupus Activity Group (BILAG)-2004 and A = 12, B = 5, C = 1. However, definitions of major and partial response in our article are identical to the definitions of complete and partial remission used by the UCL group (complete remission required reduction of all active domains to BILAG C/D, and partial remission permitted one persistent A/B, provided other domains had improved).
Our standard protocol is 100 mg methylprednisolone + 1000 mg rituximab given on days 1 and 15 with a course of prednisolone 60 mg daily on days 17 and 30 mg daily on days 814. We used CYC in only three patients. Despite using very little CYC, response rates in our study appear as good as those reported by TurnerStokes et al. [1] . Of 38 evaluable patients, 18 were receiving a concomitant immunosuppressant (6 AZA, 8 MMF, 4 MTX), providing the opportunity to compare efficacy and safety with or without these agents (Table 1) .
Confounding by indication is obviously a major limitation of this comparison, especially given the baseline difference in disease activity. However, there was no evidence of opportunistic or more frequent infections when rituximab was used in combination with a concomitant immunosuppressant in this series. In addition, we noted in our previous report [2] that plasmablast numbers were lower before and after rituximab when concomitant immunosuppressants were used, which was associated with better clinical response and is similar to a previous observation with MTX or LEF in RA [3] .
Additionally, a non-serious opportunistic infection (herpes zoster) was observed in a patient shortly after receiving two pulses of CYC with her rituximab therapy and also continued MMF. We understand the reason that concomitant immunosuppressants were discontinued in the UCL series was because of the observation of opportunistic infection in patients who had received concomitant immunosuppressants. We also note the low rates of opportunistic infection (and infection in general) in patients who received rituximab with concomitant immunosuppressants, but not CYC in the Ex-ploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial [4] . Collectively, these observations suggest that the combination of rituximab with both CYC and concomitant immunosuppressants is to blame for opportunistic infection rather than rituximab with concomitant immunosuppressants alone.
Controlled trials are required to conclusively determine the best treatment regimen. However, at present rituximab is widely used for SLE based on case series evidence and comparisons of series therefore is of value. We suggest that based on present evidence, rituximab may be used without CYC in many patients. Further, when CYC is not used, continuation of concomitant immunosuppressants is not harmful and may be beneficial. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab SIR, We present the case of a 52-year-old woman who developed RA in 1999. The patient was seropositive for both RF and anti-CCP, and erosions were detected on her X-rays. Initially MTX and then LEF were discontinued due to inefficacy. In 2004, adalimumab was started and achieved remission. Isoniazid was given for 9 months following a positive tuberculin skin test, but there was no evidence of active tuberculosis (TB). No additional DMARDs were used. During this time, two painful nodules developed on the dorsum of the second and fifth right fingers, and were surgically removed; the histological analysis was in keeping with rheumatoid nodules (RNs) and no further peripheral nodules have been noted. In 2008 the disease relapsed, and the patient was switched to etanercept, but this was stopped after a pruriginous, cutaneous rash. We decided to start the monoclonal IL-6 receptor antibody tocilizumab (TCZ), 8 mg/kg monthly, along with LEF and low-dose prednisone. With this regime, the patient remains in remission and prednisone has been successfully tapered.
Prior to treatment with TCZ, the patient complained of breathlessness on exertion and chest X-ray showed the presence of lung nodules, not seen in the radiograph prior to adalimumab. CT scan confirmed several nodules in the peripheral fields of both lungs, with sizes ranging from millimetres to centimetres, and some central cavitation was noted (Fig. 1) . Serum inflammatory markers, anti-cytoplasm neutrophil antibodies, angiotensinconverting enzyme titres and sputum culture were negative. The background of peripheral RNs made us consider the nodules as pulmonary RNs. Although the formerly treated latent TB and previous smoking habit were given consideration, it was decided not to biopsy. After 2 years on TCZ and LEF, the repeat CT scan showed a clear reduction and even disappearance of the pulmonary nodules (Fig. 1) , with no new findings.
RNs develop in about a third of patients and are more common in males, active smokers and those with seropositive disease. They are typically found in pressure points of limbs, but may also form in other parts of the body, even in organs (lungs, heart valves). Histologically, RN is a Th type-1-driven granuloma [1] .
The natural history of RNs is uncertain, but they seem to modify with RA treatment. Nodule disappearance has been reported with SSZ, penicillamine and local steroidal infiltrations [2, 3], and several reports suggest that MTX and LEF may lead to an accelerated cutaneous and pulmonary nodulosis [4, 5] . This phenomenon has also been reported with anti-TNF agents [6, 7] , although in some instances improvement has been reported [8] .
There are no data about the influence of TCZ on RNs. This was not an endpoint in pivotal controlled trials in RA [9] , and no case reports have previously addressed this. To our knowledge, this is the first report of the disappearance of pulmonary RNs with TCZ. Why TCZ might lead to the disappearance of RNs is unclear. Although increased IL-6 expression was found in $90% of the analysed nodules [10], increased TNF-a expression was also commonly observed [1] and
